Coverage
-
March 03, 2020
Genentech was on the receiving end of an upbraiding Tuesday after the Federal Circuit sensed the biotech giant had come down too harshly on the Delaware federal judge who denied its bid to block a biosimilar of a blockbuster cancer drug.
1 other articles on this case.
View all »